<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871570</url>
  </required_header>
  <id_info>
    <org_study_id>B5201006</org_study_id>
    <nct_id>NCT02871570</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function</brief_title>
  <official_title>A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Rivipansel (Pf-06460031) In Subjects With Moderate Hepatic Impairment And In Healthy Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK
      and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2016</start_date>
  <completion_date type="Actual">March 23, 2017</completion_date>
  <primary_completion_date type="Actual">February 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to infinity or area under the concentration-time curve from time 0 to the time of the last quantifiable concentration, as data permit</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours following single dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours following single dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Baseline up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of adverse events</measure>
    <time_frame>Baseline up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of 12-lead electrocardiograms</measure>
    <time_frame>Baseline up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of vital signs</measure>
    <time_frame>Baseline up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of laboratory tests</measure>
    <time_frame>Baseline up to 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours following single dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak or maximum observed concentration</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours following single dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours following single dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours following single dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Moderate Hepatic Impairment</condition>
  <condition>Normal Hepatic Function</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of IV Rivipansel over 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of IV Rivipansel over 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivipansel</intervention_name>
    <description>A single dose of IV Rivipansel over 20 minutes</description>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <other_name>GMI-1070</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of non-childbearing potential or male subjects

               -  Body Mass Index (BMI) of 17.5 to 40.0 kg/m2

               -  Normal Hepatic function for the healthy subjects

               -  Stable Hepatic Impairment for the subjects with moderate hepatic impairment

        Exclusion Criteria:

          -  Treatment with an investigational drug within 30 days of the dose of study medication

          -  Pregnant females, breastfeeding female subjects and male subjects with partners
             currently pregnant

          -  Use of herbal supplements in the 28 days prior to the dose of study medication

          -  Blood donation (excluding plasma donation) of approximately 1 pint or more within 56
             days prior to study medication

          -  A positive urine drug screen for illicit drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clincial Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5201006&amp;StudyName=A+Phase+1%2C+Non-randomized%2C+Open-label%2C+Parallel-group-single-dose+Study+To+Evaluate+The+Pharmacokinetics%2C+Safety+And+Tolerability+Of+Intravenous+Rivipansel+%28pf06460031%29+In+Subjects+With+Hepatic+Impairment+And+Healthy+Subjects+With+Normal+Hepatic+Function</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5201006&amp;StudyName=A+Phase+1%2C+Non-randomized%2C+Open-label%2C+Parallel-group+Single-dose+Study+To+Evaluate+The+Pharmacokinetics%2C+Safety%2C+And+Tolerability+Of+Intravenous+Rivipansel+%28pf-06460031%29+In+Subjects+With+Moderate+Hepatic+Impairment+And+In+Healthy+Subjects+With+Normal+Hepatic+Function</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Rivipansel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 14, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

